Prognostic factors in patients with recently diagnosed incurable cancer: A systematic review

Supportive Care in Cancer

Volumn 14, Issue 10, 2006, Pages 999-1011

  Hauser, Catherine A ^a   Stockler, Martin R ^a,b,c   Tattersall, Martin H N ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NH and MRC Clinical Trials Centre   (Australia)

Author keywords

Advanced cancer; Prognosis; Prognostic factor

Indexed keywords

ALKALINE PHOSPHATASE; LACTATE DEHYDROGENASE;

ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; BRAIN METASTASIS; CACHEXIA; CANCER PAIN; CANCER SURVIVAL; COMORBIDITY; DISEASE SEVERITY; DYSPNEA; HUMAN; HYPOALBUMINEMIA; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LUNG CANCER; MEDICAL LITERATURE; MEDICAL SPECIALIST; MEDLINE; MULTIVARIATE ANALYSIS; ONCOLOGY; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE; SOLID TUMOR; SURVIVAL TIME; SYMPTOM; SYNDROME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNIVARIATE ANALYSIS; VISCERAL METASTASIS; WELLBEING;

ANALYSIS OF VARIANCE; HUMANS; LIFE EXPECTANCY; NEOPLASMS; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 33749038665     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0079-9     Document Type: Review

References (68)

1. Christakis NA, Lamont EB (2000) Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ 320(7233):469-472
2. Glare P, Virik K, Jones M et al (2003) A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 327(7408):195
3. Chow E, Harth T, Hruby G et al (2001) How accurate are physicians' clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review. Clin Oncol (R Coll Radiol) 13(3):209-218
4. Vigano A, Dorgan M, Buckingham J et al (2000) Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliat Med 14(5):363-374
5. Maltoni M, Amadori D (2002) Prognosis in advanced cancer. Hematol Oncol Clin North Am 16(3):715-729
6. Morita T, Tsunoda J, Inoue S, Chihara S (1999) The palliative prognostic index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer 7(3):128-133
7. Pirovano M, Maltoni M, Nanni O et al (1999) A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian multicenter and study group on palliative care. J Pain Symptom Manage 17(4):231-239
8. Glare P, Virik K (2001) Independent prospective validation of the PaP score in terminally ill patients referred to a hospital-based palliative medicine consultation service. J Pain Symptom Manage 22(5):891-898
9. Milsted RA, Tattersall MH, Fox RM, Woods RL (1980) Cancer chemotherapy - what have we achieved? Lancet 1(8182):1343-1346
10. Tattersall MH, Thomas H (1999) Recent advances: oncology. BMJ 318(7181):445-448
11. Radzikowska E, Glaz P, Roszkowski K (2002) Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20561 cases. Ann Oncol13(7):1087-1093
12. Werner-Wasik M, Scott C, Cox JD et al (2000) Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48(5):1475-1482
13. Buccheri G, Torchio P, Ferrigno D (2003) Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 97(12):3044-3052
14. Le Chevalier TBD, Soria JC, Douillard JY et al (2001) Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 6(Suppl 1):8-11
15. Eton DT, Fairclough DL, Cella D et al (2003) Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 21(8):1536-1543
16. Ando M, Ando Y, Hasegawa Y et al (2001) Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 85(11):1634-1639
17. Nakahara Y, Mochizuki Y, Miyamoto Y et al (2002) Mental state as a possible independent prognostic variable for survival in patients with advanced lung carcinoma. Cancer 94(11):3006-3015
18. Kodani T, Ueoka H, Kiura K et al (2002) A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. Lung Cancer 36(3):313-319
19. MacRae R, Shyr Y, Johnson D, Choy H (2002) Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 64(1):37-40
20. Firat S, Byhardt RW, Gore E (2002) Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 54(2):357-364
21. Orditura M, De Vita F, Catalano G et al (2002) Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res 22(11):1129-1135
22. Orditura M, Romano C, De Vita F et al (2000) Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunol Immunother 49(10):530-536
23. McMillan DC, Elahi MM, Sattar N et al (2001) Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 41(1-2):64-69
24. Sloan JA, Loprinzi CL, Laurine JA et al (2001) A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. J Clin Oncol 19(15):3539-3546
25. Chow E, Fung K, Panzarella T et al (2002) A predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. Int J Radiat Oncol Biol Phys 53(5):1291-1302
26. Vigano A, Bruera E, Jhangri GS et al (2000) Clinical survival predictors in patients with advanced cancer. Arch Intern Med 160(6):861-868
27. Shadbolt B, Barresi J, Craft P (2002) Self-rated health as a predictor of survival among patients with advanced cancer. J Clin Oncol 20(10):2514-2519
28. Bachelot T, Ray-Coquard I, Catimel G et al (2000) Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 11(2):151-156
29. De Vita F, Orditura M, Galizia G et al (2000) Serum interleukin-10 is an independent prognostic factor in advanced solid tumors. Oncol Rep 7(2):357-361
30. Gamburg ES, Regine WF, Patchell RA et al (2000) The prognostic significance of midline shift at presentation on survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 48(5):1359-1362
31. Kohne CH, Cunningham D, Di CF et al (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13(2):308-317
32. Massacesi C, Norman A, Price T et al (2000) A clinical nomogram for predicting long-term survival in advanced colorectal cancer. Eur J Cancer 36(16):2044-2052
33. Maisey NR, Norman A, Watson M et al (2002) Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 38(10):1351-1357
34. Bensmaine MA, Marty M, de Gramont A et al (2001) Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/-folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. Br J Cancer 85(4):509-517
35. Massacesi C, Pistilli B, Valeri M et al (2002) Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. Am J Clin Oncol 25(2):140-148
36. Ruo L, Gougoutas C, Paty PB et al (2003) Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 196(5):722-728
37. Yuste AL, Aparicio J, Segura A et al (2003) Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. Clin Colorectal Cancer 2(4):231-234
38. Alexandre J, Bleuzen P, Bonneterre J et al (2000) Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 18(3):562-573
39. Luoma ML, Hakamies-Blomqvist L, Sjostrom J et al (2003) Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. Eur J Cancer 39(10):1370-1376
40. Kramer JA, Curran D, Piccart M et al (2000) Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36(12):1498-1506
41. Wyld L, Gutteridge E, Pinder SE et al (2003) Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer 89(2):284-290
42. Shimozuma K, Sonoo H, Ichihara K, Tanaka K (2000) The prognostic value of quality-of-life scores: preliminary results of an analysis of patients with breast cancer. Surg Today 30(3):255-261
43. Engelken FJ, Bettschart V, Rahman MQ et al (2003) Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol 29(4):368-373
44. Ridwelski K, Meyer F, Ebert M et al (2001) Prognostic parameters determining survival in pancreatic carcinoma and, in particular, after palliative treatment. Dig Dis 19(1):85-92
45. Tas F, Aykan F, Alici S et al (2001) Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 24(6):547-550
46. Ueno H, Okada S, Okusaka T, Ikeda M (2000) Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 59(4):296-301
47. Ikeda M, Okada S, Tokuuye K et al (2001) Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 91(3):490-495
48. Roychowdhury DF, Hayden A, Liepa AM (2003) Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J Clin Oncol 21(4):673-678
49. Sengelov L, Kamby C, von der Maase H (2001) Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years. Eur Urol 39(6):634-642
50. Stadler WM, Hayden A, von der Maase H et al (2002) Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 7(4):153-157
51. Sengelov L, Kamby C, Geertsen P et al (2000) Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother Pharmacol 46(5):357-364
52. Bellmunt J, Albanell J, Paz-Ares L et al (2002) Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95(4):751-757
53. Fujisaki S, Tomita R, Nezu T et al (2001) Prognostic studies on gastric cancer with concomitant liver metastases. Hepatogastroenterology 48(39):892-894
54. Louvet C, Carrat F, Mal F et al (2003) Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). Cancer Investig 21(1):14-20
55. O'Gorman P, McMillan DC, McArdle CS (2000) Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 37(1):36-40
56. De Vita F, Romano C, Orditura M et al (2001) Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 21(1):45-52
57. Shimada H, Kitabayashi H, Nabeya Y et al (2003) Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 133(1):24-31
58. Ogawa K, Toita T, Sueyama H et al (2002) Brain metastases from esophageal carcinoma: natural history, prognostic factors, and outcome. Cancer 94(3):759-764
59. Dowling AJ, Czaykowski PM, Krahn MD et al (2000) Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. J Urol 163(5):1481-1485
60. Hernes EH, Linja M, Fossa SD et al (2000) Hormone-resistant prostate cancer with symptomatic pelvic tumours: patient survival and prognostic factors. BJU Int 86(3):240-247
61. Keilholz U, Martus P, Punt CJ et al (2002) Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer 38(11):1501-1511
62. Scholz HS, Benedicic C, Haas J et al (2001) Stage IV ovarian cancer: prognostic factors and survival beyond 5 years. Anticancer Res 21(5):3729-3732
63. Ljungberg B, Landberg G, Alamdari FI (2000) Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol 34(4):246-251
64. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373-383
65. Bruera E (1997) ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ 315(7117):1219-1222
66. McMillan DC, Watson WS, O'Gorman P et al (2001) Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 39(2):210-213
67. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343(25):1846-1850
68. Yun YH, Heo DS, Heo BY et al (2001) Development of terminal cancer prognostic score as an index in terminally ill cancer patients. Oncol Rep 8(4):795-800